Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

AIM: The efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial. METHODS: Insulin-naïve subjects with type 2 diabetes [n = 458, age: 56 years, diabetes duration: 7.7 years, glycosyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Philis-Tsimikas, A, Del Prato, S, Satman, I, Bhargava, A, Dharmalingam, M, Skjøth, T V, Rasmussen, S, Garber, A J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799217/
https://www.ncbi.nlm.nih.gov/pubmed/23577643
http://dx.doi.org/10.1111/dom.12115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799217/
https://www.ncbi.nlm.nih.gov/pubmed/23577643
http://dx.doi.org/10.1111/dom.12115

Ejemplares similares